Burger Rachel L, Meffert Susan M, Ongeri Linnet, Wangia Josline, Wambura Raphael, Ajore Phanice, Rota Grace, Otieno Ammon, Obura Raymond R, Muchembre Peter, Bukusi David, Mbwayo Anne, Neylan Thomas C, Akena Dickens, Jin Chengshi, McCulloch Charles, Mathai Muthoni A
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
BMJ Glob Health. 2025 Aug 25;10(8):e017929. doi: 10.1136/bmjgh-2024-017929.
Non-adherence to antidepressants has been linked to increased symptom severity, relapse and hospitalisation from common mental disorders. However, there is limited knowledge of factors associated with antidepressant adherence in low-income and middle-income countries, especially in public sector, primary care settings.
We quantified fluoxetine adherence using the medication possession ratio. A limitation of this measure is that it does not always reflect the ingestion of medication. We constructed a generalised estimating equations linear regression with robust SEs, clustered by the participant, to identify independent predictors of fluoxetine adherence.
Participants randomised to fluoxetine were dispensed an average of 126 daily doses, or 70% of the 180 possible doses. Adherence was higher in the first half of the treatment period at 86.3%, 95% CI (83.5% to 89.2%) compared with 46.5% in the second half (44.3% to 48.8%) (p<0.001). Participants who opted for community-delivered fluoxetine demonstrated adherence at 79.7% (77.0% to 82.4%) compared with 58.6% (55.7% to 61.5%) of those who only picked up medication at the facility (p<0.001). Use of mHealth for at least one but less than half of the visits had the highest level of adherence at 84.6% (82.4% to 86.9%) compared with 49.6% (46.1% to 53.0%) among those who did not use mHealth and 67.2% (62.5% to 72.0%) for those who used mHealth at least half their visits (p<0.001).
Adherence to fluoxetine was high relative to existing selective serotonin reuptake inhibitors adherence data, the majority of which is from high-income countries. Adherence was higher during the first half of treatment. People who were older, living with HIV and opted to use community delivery of medication and/or mHealth had higher adherence.
NCT03466346.
抗抑郁药治疗依从性差与常见精神障碍症状加重、复发及住院率增加有关。然而,在低收入和中等收入国家,尤其是在公共部门的初级保健机构中,关于抗抑郁药治疗依从性相关因素的了解有限。
我们使用药物持有率来量化氟西汀的治疗依从性。该测量方法的一个局限性在于它并不总能反映药物的摄入情况。我们构建了一个广义估计方程线性回归模型,采用稳健标准误,按参与者进行聚类,以确定氟西汀治疗依从性的独立预测因素。
随机分配接受氟西汀治疗的参与者平均获得了126剂每日剂量的药物,即180剂可能剂量的70%。治疗期前半段的依从性较高,为86.3%,95%置信区间(83.5%至89.2%),而后半段为46.5%(44.3%至48.8%)(p<0.001)。选择社区配送氟西汀的参与者的依从性为79.7%(77.0%至82.4%),而仅在医疗机构取药的参与者的依从性为58.6%(55.7%至61.5%)(p<0.001)。在至少一次但少于一半的就诊中使用移动健康技术的参与者的依从性最高,为84.6%(82.4%至86.9%),未使用移动健康技术的参与者的依从性为49.6%(46.1%至53.0%),至少一半就诊使用移动健康技术的参与者的依从性为67.2%(62.5%至72.0%)(p<0.001)。
相对于现有的选择性5-羟色胺再摄取抑制剂治疗依从性数据而言,氟西汀的治疗依从性较高,现有数据大多来自高收入国家。治疗前半段的依从性更高。年龄较大、感染艾滋病毒且选择社区配送药物和/或移动健康技术的人依从性更高。
NCT03466346。